The global biological indicators market size was estimated at USD 572.28 million in 2025 and is projected to reach USD 1.10 billion by 2033, growing at a CAGR of 8.78% from 2026 to 2033. This growth is attributed to the growing emphasis on sterilization and infection control across healthcare, pharmaceutical, and food industries.
Increasing concerns over hospital-acquired infections (HAIs) and stringent regulatory requirements for validating sterilization processes are boosting demand for reliable and rapid BI solutions. In addition, advancements in rapid-readout and automation technologies, coupled with the rising adoption of sterilization methods in emerging markets, are further accelerating the growth of the market. Stringent regulatory requirements play a pivotal role in driving the biological indicators industry, as global health authorities mandate the validation of sterilization processes across industries such as medical devices, pharmaceuticals, and biotechnology. Biological indicators are the gold standard for confirming sterilization efficacy, making them a necessity for compliance. For instance, the U.S. Food and Drug Administration (FDA) requires medical device manufacturers to demonstrate sterilization validation under 21 CFR Part 820 (Quality System Regulation), while the European Medicines Agency (EMA) and the ISO 11138 standard outline specific criteria for biological indicator use in sterilization assurance. Similarly, compliance with Good Manufacturing Practices (GMP) in pharmaceuticals necessitates biological indicator-based validation for sterilized drug products and equipment. These strict regulatory frameworks ensure patient safety and product reliability, fueling consistent demand for biological indicators across critical healthcare and life sciences sectors.
The rising burden of hospital-acquired infections (HAIs) is a key factor driving the growth of the biological indicators industry, as healthcare facilities are increasingly focusing on strengthening infection control and sterilization practices. According to the WHO’s Global Report on Infection Prevention and Control 2024, a large-scale systematic review of nearly 400 studies estimated the global prevalence of HAIs at around 14% in 2023. Furthermore, a European point prevalence survey conducted in 2022/2023 across 28 EU/EEA countries and three Western Balkan nations/territories reported an adjusted prevalence of 8% for patients with at least one HAI. This growing incidence of HAIs underscores the critical need for reliable sterilization validation, fueling the demand for biological indicators to ensure the effectiveness of sterilization processes over the forecast period.
This product will be delivered within 1-3 business days.
Increasing concerns over hospital-acquired infections (HAIs) and stringent regulatory requirements for validating sterilization processes are boosting demand for reliable and rapid BI solutions. In addition, advancements in rapid-readout and automation technologies, coupled with the rising adoption of sterilization methods in emerging markets, are further accelerating the growth of the market. Stringent regulatory requirements play a pivotal role in driving the biological indicators industry, as global health authorities mandate the validation of sterilization processes across industries such as medical devices, pharmaceuticals, and biotechnology. Biological indicators are the gold standard for confirming sterilization efficacy, making them a necessity for compliance. For instance, the U.S. Food and Drug Administration (FDA) requires medical device manufacturers to demonstrate sterilization validation under 21 CFR Part 820 (Quality System Regulation), while the European Medicines Agency (EMA) and the ISO 11138 standard outline specific criteria for biological indicator use in sterilization assurance. Similarly, compliance with Good Manufacturing Practices (GMP) in pharmaceuticals necessitates biological indicator-based validation for sterilized drug products and equipment. These strict regulatory frameworks ensure patient safety and product reliability, fueling consistent demand for biological indicators across critical healthcare and life sciences sectors.
The rising burden of hospital-acquired infections (HAIs) is a key factor driving the growth of the biological indicators industry, as healthcare facilities are increasingly focusing on strengthening infection control and sterilization practices. According to the WHO’s Global Report on Infection Prevention and Control 2024, a large-scale systematic review of nearly 400 studies estimated the global prevalence of HAIs at around 14% in 2023. Furthermore, a European point prevalence survey conducted in 2022/2023 across 28 EU/EEA countries and three Western Balkan nations/territories reported an adjusted prevalence of 8% for patients with at least one HAI. This growing incidence of HAIs underscores the critical need for reliable sterilization validation, fueling the demand for biological indicators to ensure the effectiveness of sterilization processes over the forecast period.
Global Biological Indicators Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global biological indicators market report based on product, method, end use, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Self-Contained (Vials/Ampoules)
- Strips
- Cards / Rapid Readout BIs
- Others
Method Outlook (Revenue, USD Million, 2021-2033)
- Steam Sterilization
- Ethylene Oxide Sterilization
- Hydrogen Peroxide Sterilization
- Irradiation Sterilization (Gamma, E-beam)
- Dry Heat Sterilization
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals & Clinics (CSSD / Infection Control Units)
- Ambulatory Surgery Centers (ASCs) & Dental Clinics
- Biopharma & Biotech Companies
- Medical Device Manufacturers
- Contract Sterilization Service Providers
- Research & Academic Institutes
- Other End Uses
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Biological Indicators Market Variables, Trends, & Scope
Chapter 4. Biological Indicators Market: Product Estimates & Trend Analysis
Chapter 5. Biological Indicators Market: Method Estimates & Trend Analysis
Chapter 6. Biological Indicators Market: End Use Estimates & Trend Analysis
Chapter 7. Biological Indicators Market: Regional Estimates & Trend Analysis by Product, Method, End Use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- STERIS plc.
- Solventum
- Getinge
- Mesa Laboratories, Inc.
- 3M
- Terragene S.A.
- Propper Manufacturing Co., Inc.
- Tuttnauer
- Ecolab Inc.
- H.W.Andersen Products Ltd.
- MATACHANA GROUP
- LISTER BIOMEDICAL CO., LTD
- Liofilchem S.r.l.
- Steelco S.p.A
- Zhejiang Tailin Bioengineering Co., Ltd.
- Cole-Parmer Instrument Company, LLC (Antylia Scientific)
- Anhui Tianrun Medical Packaging Materials Co., Ltd.
- Medline Industries, LP.
- True Indicating
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 572.28 Million |
| Forecasted Market Value ( USD | $ 1100 Million |
| Compound Annual Growth Rate | 8.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 19 |
